Orange Coast Magazine Top Doctors 2025

695 Physicians | 84 Specialties

This year’s Physician’s of Excellence were judged by the Orange County Medical Association to be among the most accomplished and caring.

DERMATOLOGY
Kristen M. Kelly
Laser surgery, vascular birthmarks
Irvine
949-824-5515

FACIAL PLASTIC AND RECONSTRUCTIVE SURGERY
Brian J. F. Wong
Rhinoplasty, revision rhinoplasty, nasal reconstruction
Irvine
714-456-7017

NEUROLOGY
Yama Akbari
Neurocritical care, coma, consciousness, cardiac arrest
Irvine
949-824-1888

Mark J. Fisher
Stroke
Orange
714-456-5091

Click here to see full listing in Orange Coast Magazine.

Nanour Arakelian and Mary Javaherian of the Wilder-Smith Lab receive UC Irvine Undergraduate Research Opportunities Program Travel and Research Experience Fellowship Awards

Student researchers Nanour Arakelian and Mary Javaherian were awarded UC Irvine Undergraduate Research Opportunities Program (UROP) Travel and Research Experience Fellowship Awards for dental research conducted in the laboratory of Dr. Petra Wilder-Smith at UC Irvine Beckman Laser Institute & Medical Clinic.

The UROP Research Experience Fellowship Award provides recognition and funding to UC Irvine undergraduate students from various disciplines in support of research or creative activities under the guidance of UC Irvine faculty members.  Arakelian and Javaherian will present their research projects at the annual UC Irvine Undergraduate Research Symposium in May 2025.

The UROP Travel Award provides recognition and funding for awardees’ research-related travel or publication expenses.  The award will support Arakelian and Javaherian’s presentation at the 54th Annual Meeting and Exhibition of the American Association for Dental, Oral, and Craniofacial Research (AADOCR) and the 49th Annual Meeting of the Canadian Association for Dental Research (CADR) on March 12-15, 2025, in New York City, New York.

The AADOCR is the leading professional community for multidisciplinary scientists who advance dental, oral and craniofacial research.  Arakelian and Javaherian look forward to attending the annual meeting, which will feature oral and poster presentations, hands-on workshops, lunch and learn sessions, keynote addresses and symposia presented by experts from around the world.

Click here to learn more about the Dr. Petra Wilder-Smith Laboratory at UC Irvine Beckman Laser Institute & Medical Clinic.

Click here to learn more about the UC Irvine UROP.

Click here to learn more about the AADOCR and CADR.

Will Modulim End the Amputation Epidemic?

Using light projections to see beneath the skin, Modulim’s device detects subtle changes in a diabetic patient’s microvascular circulation.

By Jill Kato, UC Irvine Beall Applied Innovation, December 17, 2024

By reducing the need for diabetes-related amputations, Modulim is poised to achieve the biotech trifecta: improve patient outcomes, deliver cost-savings to insurance companies, and streamline physicians’ workload.

David Cuccia will never forget sitting in Professor Bruce Tromberg‘s office with a group of faculty when the conversation shifted to the future of their research. A company had recently approached UC Irvine to license their technology and Cuccia, then a graduate student, turned to the faculty to ask what they planned to do about the offer.

“David, we’re faculty,” they said. “The question is, what are you going to do about it?’”

Cuccia realized he wasn’t interested in licensing the technology to someone else. Instead, he logged on to Legal Zoom to set up his own company for $250 that night.

That company was Modulated Imaging Inc., now known as Modulim, a medical device startup focused on preserving human limbs with medical imaging technology. With Cuccia as chief technology officer, Modulim is set to bring transformative changes to the field of diabetes care.

Curiosity Meets Innovation

Cuccia first arrived at UC Irvine as a freshman and lived at The Shire in the Middle Earth dorms. Initially, he saw himself becoming a doctor. Since he liked science and helping people, he assumed this would be his path. But after witnessing his first surgery, Cuccia knew medicine wasn’t for him. He switched to physics and joined Tromberg’s lab. The undergraduate research he conducted there eventually grew into Modulim, a venture that would come to define his career.

As Cuccia began planning for life after graduation, Professor Anthony Durkin suggested that writing a few more papers could allow him to quickly earn a Ph.D. Taking this advice, Cuccia decided to stay on and pursue his doctorate. Durkin was right about the timeframe. The average time to complete a Ph.D. in biomedical engineering is five to six years. Cuccia earned his in three and a half.

At the time, researchers at the Beckman Laser Institute had spotted a fascinating new trend. Combining near-infrared light and digital projectors, the researchers were able to capture extensive information about tissue in a novel manner. Cuccia and his colleagues invented Spatial Frequency Domain Imaging (SFDI), a non-invasive light-based imaging technique that can capture data on oxygen levels and hemoglobin concentrations in the skin. Instead of a single data point, SFDI captures whole images and examines tissue up to five millimeters deep. Moreover, it’s much quicker than other assessment methods, delivering widefield results in seconds without exposing patients to harmful radiation.

While a graduate student, Cuccia successfully applied for Small Business Innovative Research (SBIR) grants. By the time he graduated, he was able to transition from a Ph.D. student to a principal investigator with his own company. He also discovered that other researchers wanted to buy devices like the one he had built in the lab.

As Cuccia transitioned from graduate student to founder of a startup, Amaan Mazhar arrived at UC Irvine to start his Ph.D. in biomedical engineering. This turned out to be serendipitous. Not only was Mazhar interested in Cuccia’s work, but he was passionate about solving real-world problems.

“The growth of knowledge and technology development was fueled by Amaan. He was director of research, building the devices, and in charge of clinical collaborations. He’s been my partner in crime from the beginning,” says Cuccia. Mazhar now serves as Modulim’s CEO.

In his pitch to the first round of investors, Cuccia introduced a versatile platform with a diverse range of potential applications. Because the technology provided a lens into the properties of tissue and materials, potential applications included improving outcomes of surgical procedures, advancing wound care, and even streamlining fruit inspection. Out of the gate, Cuccia and Mazhar wanted to make sure they helped the most people and made the biggest impact. Their challenge lay in figuring out where to focus their attention first.

Revolutionizing Diabetic Foot Care

Through their clinical collaborations, Cuccia and Mazhar learned more about the scale of the amputation epidemic. Every 20 seconds a person with diabetes undergoes a lower-limb amputation. Poor circulation in diabetes patients starves tissue of nutrients and leads to a breakdown of the skin, which results in chronic ulcers. Nerve damage, a common complication of diabetes, often masks the symptoms of these ulcers. As a result, patients may not even know they have an issue until a chronic ulcer has formed, leading to infection, gangrene, and hospitalizations. In severe cases, this can lead to the need for amputation.

In addition to the personal trauma of losing part of a lower limb, amputations come with significant financial costs. In total, the treatment of diabetic limb-related complications costs about $17 billion in the United States, which is more than the top five most costly cancers.

In a healthcare system that prioritizes treating acute conditions over preventative care, busy physicians often lack the resources to perform foot assessments on all diabetes patients. While it’s possible to train other healthcare personnel to conduct these exams, the current approach still isn’t ideal, since it is highly subjective and dependent on level of skill and interpretation. To effectively address this healthcare gap, Modulim plans to take the subjectivity and guesswork out of diabetic foot exams and make them widely available.

While light is ubiquitous in wearable devices like Fitbits and Apple watches, Modulim’s device uses light projections to see beneath the skin, detecting subtle changes in a patient’s microvascular circulation. Cuccia’s team is developing a handheld version of the technology that is about the size and shape of a smartphone, where a technician with minimal training could operate it in community settings. The device would be compact enough for healthcare personnel to carry in their bags, allowing them to bring it on home visits or to nursing homes.

Integrating a Multidisciplinary Problem

Besides subjectivity, accessibility, and cost, Modulim’s technology tackles another critical aspect of the amputation crisis. Diabetic foot care is a complex, multidisciplinary problem involving physicians from various specialties. A patient with diabetes could potentially see a primary care physician, an endocrinologist, a nephrologist, a vascular medicine specialist, and a podiatrist. Their provision of care often remains fragmented, with no single discipline taking lead.

“We can bridge these specialties by introducing an objective and quantifiable assessment that everyone can use,” says Mazhar.

To complement the device, Modulim has developed cloud-based software to help clinicians in care-management, to help track patients, monitor their microvascular changes, and to share insights within an organization. The device, combined with the algorithm and cloud-based software, has the potential to greatly enhance front-line diabetic care.

Collaborative Roots

The first office space Modulim used was, in fact, a converted printer closet. To help get the startup off the ground, UC Irvine faculty rearranged their postdocs so Cuccia and Mazhar could have a small space. Humble as it was, they were grateful for the “office,” especially since it was in UC Irvine’s Beckman Laser Institute, where groundbreaking work like theirs was taking place.

“Maybe they helped with the space out of pity, but I’m thankful for it,” says Cuccia. “I felt like we had a hundred percent support from everyone all of the time. They wanted to make this happen for us.”

In moving the invention from a university research discovery into a product in the private sector, Cuccia appreciates the freedom and fairness of the deals he’s made with UC Irvine through UCI Beall Applied Innovation.

“They gave us a long leash in terms of the initial fund repayment timeline. They understood that our need for cash was critical. This gave us a solid foundation to find the right fit,” he says.

As a licensing officer for UCI Beall Applied Innovation, Alvin Viray ensured that Cuccia had the support and resources he needed to protect and commercialize his Ph.D. research.

“It has been incredibly rewarding to see his ideas grow into a venture that has real potential to impact the health industry and patients,” Viray says.

These resources and support have generated a lot of loyalty from Cuccia and Mazhar. Even for a UC Irvine-born and incubated startup, their connection and loyalty to the university is deep. They take part in round tables and advisory boards. Their workforce includes a significant number of UC Irvine alumni. They work closely with UC Irvine Beall Applied Innovation by mentoring other startups and by speaking at events. Cuccia serves on the Campuswide Honors Collegium advisory board and Mazhar reviews Proof of Product (PoP) grants in his spare time. Both Mazhar and Cuccia even met their spouses while students at UC Irvine.

“UCI remains supportive of us, and we do our best to contribute in return,” Cuccia says.

A Bold Vision for Healthcare and Beyond

Modulim has attracted over ten million dollars in grants and private investment. Their solution has been rolled out with multiple partners, including Fresenius dialysis clinics, University of Arizona, University of Southern California, and Kaiser Permanente, to study patient populations with a heightened risk of amputation.

And diabetic foot care is only the beginning. With a $2.5 million dollar contract from the Department of Defense, Modulim has partnered with Anthony Durkin in UCI’s biomedical engineering department to build a tool for digital assessment of burns using their technology. Durkin’s lab has already demonstrated the ability of machine learning to map the area and severity of burns using Modulim’s proprietary outputs.

Moreover, the startup can tackle much more than just healthcare. Its technology has been used by research collaborators to understand skincare products, characterize produce quality, and visualize inks in tattoos and old manuscripts. The technology can also be applied in augmented reality by rendering a person’s appearance under different lighting conditions, utilizing a deeper understanding of how light interacts with skin.

But these projects are awhile away. Cuccia jokes that maybe when he’s retired, he’ll be able to work on these broader applications. For now, Modulim is focused on bringing their newest handheld version of their system to market. Understanding that collaborating with major payers and providers is crucial for commercial success, Modulim’s strategy aligns with the healthcare shift toward value-based care models, which focus on reducing costs and improving patient outcomes.

“If there’s a way that technology can help even the playing field and get patients earlier and better access to care,” says Mazhar, “it’s an opportunity for us to contribute to improving our health system.”

Learn more at: https://modulim.com/.

Click here to read the full article on the UC Irvine Beall Applied Innovation website.

Clinical Innovation Incubator Program recognizes inaugural awardees

Posted: 2024-12-16

Source: UCI School of Medicine

UC Irvine Department  Dermatology, UC Irvine School of Medicine and UCI Health, in partnership with UC Irvine Beall Applied Innovation, recently launched a new initiative, called the Clinical Innovation Incubator Program, to foster collaborations among clinicians, basic scientists and engineers, and industry mentors to develop innovative solutions for clinical needs.

During a series of three workshops, candidates pitched their clinical problem and then worked with mentors and collaborators to create an innovative solution. The inaugural program saw eight incredible proposals and the following two awardees were selected to receive $50,000 each to further develop their innovations that will address a clinical need: Anand Ganesan, MD, PhD, professor of dermatology, for his project “Developing a New Vascular Targeted Treatment for Rosacea,” and Andrew Creadore, MD, a PGY-4 resident in the Department of Dermatology, for his project “Mobile App to Fill Gap in Natural Broadband Phototherapy Treatment Guidance.”

Congratulations to the awardees of the inaugural Clinical Innovation Incubator Program, and stay tuned for information on the next round of the Clinical Innovation Incubator Program that will be held in 2025.

Click here to read the full UCI School of Medicine newsroom announcement.

Video: Vascular Neurology Considerations for Anti-Amyloid Immunotherapy

Authors Mark Fisher, MD and Steve Greenberg, MD announce the publication of the science advisory in the journal STROKE and discuss predictors of ARIA, the use of antithrombotic and thrombolytic medications in patients receiving anti-amyloid therapy, and suggested treatment approaches.

C

Read more on the American Heart Association Daily website.

Click here to watch video on YouTube.

Image-Guided Precision Radiotherapy

Your support in the 2022 UCI Anti-Cancer Challenge helped fuel this project led by UC Irvine School of Medicine Associate Professor, Liangzhong Xiang, PhD.

Watch the video and discover more about the research you helped fund!

Xiang’s Anti-Cancer Challenge Funded Research

When treating cancer with radiation therapy, imaging is crucial to help plan and deliver the treatment effectively.

With the emergence of a new type of radiation therapy called FLASH, new imaging techniques are needed to account for daily changes during treatment. Researchers are working on a new imaging modality called radiation-induced acoustic imaging, which will provide real time 3D dose verification for FLASH therapy.

This new technology will help ensure that the treatment is delivered precisely and accurately to the tumor and healthy tissues. This breakthrough can lead to a paradigm shift in using FLASH-RT for cancer treatment, which can benefit patients who may suffer from radiation-induced toxicities.

Click here to view the video on YouTube.

Pushing Cancer Treatment into the Future

Lumitron Technologies, a company housed in the UC Irvine Research Park and co-founded by Professor Christopher Barty of the UC Irvine Department of Physics & Astronomy, is developing a novel X-ray and electron beam machine called HyperVIEW™ that aims to selectively image cancer in the body and eliminate it while minimizing damage to surrounding tissue.

“The machine has now generated electron beams that can be used to treat cancer anywhere in the human body and x-ray beams that follow the same path as the electrons that can image cancer at 100 times beyond the resolution of conventional clinical systems,” said Barty. “The holy grail is that ultimately you will have the ability to guide your cancer treatment in ways that nobody’s ever been able to do before.” HyperVIEW™ is a fourth-generation, laser-Compton X-ray technology Barty started developing when he was a scientist at Lawrence Livermore National Laboratory. HyperVIEW™ X-rays will “allow you to image soft tissues at potentially cellular levels, something that has only ever been done at billion-dollar synchrotron facilities,” Barty said, which means Lumitron’s technology could one day both track and treat cancer at the cellular level in the human body. The company plans to have FDA approval for initial, precision cancer imaging applications by late 2025 and moved HyperVIEW™ to pre-clinical cancer treatment studies late this summer. “With this technology, we may eliminate the need to ever remove a breast or prostate again,” said Barty.

Click here to read the 2024 UC Irvine Physical Sciences Dean’s Report.

Resilience leads to better outcomes

Dr. Thair Takesh designs novel dental device to minimize the spread of infection

In 2015, Dr. Thair Takesh, a dental surgeon, periodontist and implantologist, joined the lab of Dr. Petra Wilder-Smith at UC Irvine Beckman Laser Institute & Medical Clinic.  With his specialty background, he found a home, contributing to technology development, commercialization and clinical research studies in oral health.

“It was a great partnership,” stated Dr. Takesh.  “Dr. Wilder-Smith was looking to expand her work.  Having advanced surgical training, I was able to address complex issues of the tooth and handle dental implants, contributing a different skill set to the team.”

Since then, Dr. Takesh’s research has spanned a wide range of topics.  This includes developing low-cost optical techniques for detecting microcracks in teeth; creating an artificial intelligence (AI)-powered low-cost pen for the detection and monitoring of acute and chronic wound infection by non-specialists and innovating several noninvasive approaches to mapping and monitoring gingival and periodontal health.

“As a clinician, I have the opportunity to assess the needs of dental professionals, consult on the existing projects and test protypes to provide feedback,” stated Dr. Takesh.  “My aim is to improve the lives of dentists and hygienists, as well as enhance outcomes for patients.”

Dr. Takesh’s latest project is designing and validating a novel aerosol-eliminating dental ultrasonic scaler to minimize the spread of infection between patients and dental professionals.  Ultrasonic scaling is known for producing the highest emissions and risk among dental and medical tools. However, current technologies that address this issue are costly, cumbersome, time-consuming and ineffective.  Dr. Takesh’s work seeks to overcome these challenges, providing a more effective, efficient and practical solution.

“The idea came after COVID, where the spread of infection was of high concern.  During dental procedures, saliva, blood, plaque and other liquids or invisible particles are suspended in the air from the patient’s mouth.” stated Dr. Takesh. “These aerosols remain airborne for up to three days, land on surfaces and potentially reach the lungs if there is no adequate way to alleviate the problem.”

The innovative dental ultrasonic scaler effectively evacuates 82 percent to 95 percent of dental aerosol and droplets directly at the source, thereby preventing the spread of airborne bacteria and viruses.  The design offers several benefits.  This includes reducing entry of infectious materials from entering the dental clinic environment, minimizing personnel costs by eliminating the need for an assistant to perform intra-operative suction and supporting clinicians by reducing musculoskeletal fatigue and injury through improved ergonomics.

“In working with Dr. Wilder-Smith, I am always learning and gaining new skills,” stated Dr. Takesh.  Often, I must shift my thinking from a traditional dentistry perspective to the mindset of a biomedical engineer.  I enjoy discovering a solution to each challenge.”

Dr. Takesh developed various methods to quantify the efficacy of the proposed design.  These approaches include mapping reductions in aerosols and droplets, measuring distance of the spread and completing thermal measurements to ensure that the device cools effectively. 

“Like with many inventions, there have been numerous iterations of this protype,” stated Dr. Takesh.  “With each iteration, we validate the design’s effectiveness and make improvements, continuously repeating this cycle until the risk of infection is minimized, while ensuring safe dental practices.”

Upon successful completion of the project, Dr. Takesh envisions translating the technology to multiple other dental and medical power-driven devices.  This could potentially enhance safety and efficacy across various healthcare settings by minimizing infection associated with aerosol generating procedures.

“Dr. Takesh’s contributions are invaluable in the field of dental and medical technology,” stated Dr. Wilder-Smith.  “His efforts showcase his ability to drive meaningful advancements in healthcare, positively affecting the lives of practitioners and patients worldwide.”

Beginnings in Syria

Dr. Takesh’s journey to UC Irvine was marked by significant challenges and resilience, with roots in Aleppo, Syria.  At the age of 12, his father was jailed for opposing the Syrian regime.  This left Dr. Takesh, the eldest son of seven children, with the responsibility of helping to raise his siblings.

“My father was jailed for 17 years,” stated Dr. Takesh.  “He never saw a judge or was brought to court.  He disappeared for a long period of time, and we went without knowing if he was alive or had died in jail.” 

In addition to caring for his family, he spent his childhood in a constant state of fear under the dictatorship regime.  This fear is encapsulated by a well-known saying in Syria, “the walls have ears.”

“We couldn’t even whisper,” stated Dr. Takesh.  “We were terrified of being punished for saying the slightest thing.”

Despite these hardships, Dr. Takesh’s mother prioritized education.  With the help of scholarships, she was able to send him and his siblings to private school.  This provided a healthier environment for the children.  This focus on education, along with Dr. Takesh’s dedication and passion for learning, enabled him to excel academically.  His strong academic performance led him to a career in dentistry.

“In dentistry, each person and each tooth are different,” stated Dr. Takesh.  “You are constantly using your hands, which means you continually have to improve your skills.”

In 2000, Dr. Takesh temporarily closed his twenty-year-old dental practice in Aleppo to pursue further specialty training in implantology and prosthodontics in the United Kingdom.  During this time, his wife, Amal Alachkar, was furthering her education by pursuing her Ph.D.  This period of advanced training and education allowed Dr. Takesh the opportunity to enhance his expertise.

Upon returning to Aleppo, Dr. Takesh re-established his practice, specializing in periodontology, oral implantology, temporomandibular joint (TMJ) disorder and prosthodontics.  He also pursued an additional master’s degree in biomechanical engineering, which provided him with a biomechanistic understanding of many oral dysfunctions.  This multidisciplinary approach enriched his practice, allowing him to address complex dental issues with a comprehensive perspective.

“During this time, I was going to school, teaching and working at my practice,” stated Dr. Takesh.  “The money that I earned, provided for my mother and siblings.  In Syrian culture, you prioritize family much more than in Western cultures.  You support one another without having to ask.”

Coming to the U.S.

In 2011, Dr. Takesh traveled to the United States when Dr. Alachkar was awarded a one-year Hubert H. Humphrey Fellowship to study at Penn State.  However, with the outbreak of civil war in Syria, the couple and their two children were unable to return to their home country.  This unexpected turn of events led the family to build an entirely new life in the states.

“When the revolution started, we thought it would be temporary, but it worsened and the regime was bombing our country – our city,” stated Dr. Takesh.  “We had spent our whole life saving to establish ourselves in our country.”

“We had left our house, our belongings – everything,” he stated. “It was impossible to go back.”

One year later, after the unbelievable challenge of starting anew, the family moved to California.  Dr. Alachkar, a neuroscientist, joined the UC Irvine School of Pharmacy and Pharmaceutical Sciences. With no dental school on campus, Dr. Takesh spent the next two years working without pay in the Department of Chemical Engineering.  Eager to pursue something related to his profession, he was introduced to the only dentist at UC Irvine, Dr. Wilder-Smith, by Dr. Olivier Civelli, Eric L. and Lila D. Nelson Chair in Neurpharmacology and Professor of Pharmaceutical Sciences and Developmental & Cell Biology.

Returning to Syria

Besides dentistry, Dr. Takesh is passionate about serving underserved communities, particularly in his home country.  For the past three years, he has partnered with humanitarian organizations to provide aid to hundreds of refugees.  He hosts lectures about oral health at local universities, trains dental students and offers free dental care and performs oral surgeries for refugees.

“I typically fly into neighboring countries, like Turkey or Lebanon, then drive to the refugee camps in an area out of regime control,” stated Dr. Takesh.  “If I were to travel outside of this area, then I would be arrested and potentially jailed for the rest of my life.”

With over 2 million refugees residing in this compact area, these clinics provide critical access to healthcare for many displaced Syrians. During the few weeks that Dr. Takesh is in the country, he dedicates his time to helping as many people as possible.  His efforts make a significant difference in the lives of refugees, providing dental care amidst challenging circumstances.

“With the hardships that people face in the camps, oral health is the last thing on their minds,” stated Dr. Takesh.  “I stress the importance of teeth cleaning and the relationship between oral care and other diseases, especially those that affect the heart.”

It is not only the physical hearts of the patients that Dr. Takesh worries about, but also the emotional well-being of those he serves.  Having been displaced himself, he understands the country, the language and profound effects of trauma and stress.  This shared experience allows him to connect deeply with his patients, offering not only medical care, but also empathy.

“These overpopulated camps were designed to be temporary, but they are seemly permanent,” stated Dr. Takesh.  “It’s one thing to hear stories, but to witness the situation with my own eyes was above and beyond what I could have ever imagined. “  

Today, Dr. Takesh feels fortunate to have connected with Dr. Wilder-Smith and the opportunities that working at the Institute has provided.  It has allowed him to continue his professional journey and integrate his passion for dentistry with his commitment to serving others both locally and globally.  This partnership has opened many doors for collaboration and growth.

“It gave my life meaning again,” stated Dr. Takesh.  “I am fortunate to have raised my kids in a safe area, surrounded by kind people and having helped others – being able to help others is the most important thing.” 

“[As a Syrian,] it has been a difficult life, but perhaps a hard life makes you a better person,” he stated.

Facts about Syria

  • After over a decade of conflict, Syria remains the world’s largest refugee crisis.
  • Since 2011, more than 14 million Syrians have been forced to flee their homes in search of safety.
  • More than 7.2 million Syrians remain displaced in their own country where 70 percent of the population needs humanitarian assistance and 90 percent live below the poverty line.

 Figures based on USA for The United Nations Refugee Agency

Click here to learn more about the lab of Dr. Petra Wilder-Smith.

 

 

 

 

 

A trick of light: UC Irvine researchers turn silicon into direct bandgap semiconductor

Discovery enables manufacturing of ultrathin solar panels, advanced optoelectronics

Irvine, Calif., Oct. 31, 2024 — By creating a new way for light and matter to interact, researchers at the University of California, Irvine have enabled the manufacturing of ultrathin silicon solar cells that could help spread the energy-converting technology to a vast range of applications, including thermoelectric clothing and onboard vehicle and device charging.

The development, subject of a paper recently published as the cover story in the journal ACS Nano, hinges on the UC Irvine researchers’ conversion of pure silicon from an indirect to a direct bandgap semiconductor through the way it interacts with light.

The UC Irvine team, in collaboration with scientists from Russia’s Kazan Federal University and Tel Aviv University, explored an innovative approach by conditioning the light rather than changing the material itself. They confined photons on sub-3-nanometer asperities near the bulk semiconductor, granting light a novel property – expanded momentum – that opens new interaction pathways between light and matter. By “decorating” the silicon surface, the researchers said, they achieved a boost in light absorption by orders of magnitude, along with a significant increase in device performance.

“In direct bandgap semiconductor materials, electrons transition from the valence band to the conduction band. This process requires only a change in energy; it’s an efficient transfer,” noted lead author Dmitry Fishman, UC Irvine adjunct professor of chemistry. “In indirect bandgap materials, like silicon, an additional component – a phonon – is needed to provide the electron the momentum necessary for the transition to occur. Since the likelihood of a photon, phonon and electron interacting at the same place and time is low, silicon’s optical properties are inherently weak.”

He said that as an indirect bandgap semiconductor, silicon’s poor optical properties limit the development of solar energy conversion, and optoelectronics in general, which is a drawback considering that silicon is the second-most abundant element in Earth’s crust and the foundation on which the world’s computer and electronics industries were built.

“Photons carry energy but almost no momentum, but if we change this narrative explained in textbooks and somehow give photons momentum, we can excite electrons without needing additional particles,” said co-author Eric Potma, UC Irvine professor of chemistry. “This reduces the interaction to just two particles, a photon and an electron, similar to what occurs in direct bandgap semiconductors, and increases light absorption by a factor of 10,000, completely transforming light-matter interaction without changing the chemistry of the material itself.”

Co-author Ara Apkarian, UC Irvine Distinguished Professor emeritus of chemistry, said: “This phenomenon fundamentally changes how light interacts with matter. Traditionally, textbooks teach us about so-called vertical optical transitions, where a material absorbs light with the photon changing only the electron’s energy state. However, momentum-enhanced photons can change both the energy and momentum states of electrons, unlocking new transition pathways we hadn’t considered before. Figuratively speaking, we can ‘tilt the textbook,’ as these photons enable diagonal transitions. This dramatically impacts a material’s ability to absorb or emit light.”

According to the researchers, the development creates an opportunity to exploit recent advances in semiconductor fabrication techniques at the sub-1.5-nanometer scale, which has the potential to affect photo-sensing and light-energy conversion technologies.

“With the escalating effects of climate change, it’s more urgent than ever to shift from fossil fuels to renewable energy. Solar energy is key in this transition, yet the commercial solar cells we rely on are falling short,” Potma said. “Silicon’s poor ability to absorb light means that these cells require thick layers – almost 200 micrometers of pure crystalline material – to effectively capture sunlight. This not only drives up production costs but also limits efficiency due to increased charge carrier recombination. The thin-film solar cells that are one step closer to reality due to our research are widely seen as the solution to these challenges.”

Other co-authors on this study included Jovany Merham and Aleksey Noskov of UC Irvine; Kazan Federal University researchers Elina Battalova and Sergey Kharintsev; and Tel Aviv University investigators Liat Katrivas and Alexander Kotlyar. The project received financial support from the Chan Zuckerberg Initiative.

About UC Irvine’s Brilliant Future campaign: Publicly launched on Oct. 4, 2019, the Brilliant Future campaign aims to raise awareness and support for the university. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UC Irvine seeks to reach new heights of excellence in student success, health and wellness, research and more. The School of Physical Sciences plays a vital role in the success of the campaign. Learn more by visiting https://brilliantfuture.uci.edu/uci-school-of-physical-sciences.

About the University of California, Irvine: Founded in 1965, UC Irvine is a member of the prestigious Association of American Universities and is ranked among the nation’s top 10 public universities by U.S. News & World Report. The campus has produced five Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UC Irvine has more than 36,000 students and offers 224 degree programs. It’s located in one of the world’s safest and most economically vibrant communities and is Orange County’s second-largest employer, contributing $7 billion annually to the local economy and $8 billion statewide. For more on UC Irvine, visit www.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus studio with a Comrex IP audio codec to interview UC Irvine faculty and experts, subject to availability and university approval. For more UC Irvine news, visit news.uci.edu. Additional resources for journalists may be found at https://news.uci.edu/media-resources.

Click here to read full article on UC Irvine News.

Photodynamic Therapy Found to Reduce Rhytides, Improve Dyspigmentation

Doug Brunk, Medscape

Photodynamic therapy (PDT) — a treatment most commonly thought of for field cancerization — is an effective tool for reducing rhytides and lentigines, results from a small prospective study showed.

“Our study helps capture and quantify a phenomenon that clinicians who use PDT in their practice have already noticed: Patients experience a visible improvement across several cosmetically important metrics including but not limited to fine lines, wrinkles, and skin tightness following PDT,” one of the study authors, Luke Horton, MD, a fourth-year dermatology resident at the University of California, Irvine, said in an interview following the annual meeting of the American Society for Dermatologic Surgery, where he presented the results during an oral abstract session.

For the study, 11 patients underwent a 120-minute incubation period with 17% 5-aminolevulinic acid over the face, followed by visible blue light PDT exposure for 16 minutes, to reduce rhytides. The researchers used a Vectra imaging system to capture three-dimensional images of the patients before the procedure and during the follow-up. Three dermatologists analyzed the pre-procedure and post-procedure images and used a validated five-point Merz wrinkle severity scale to grade various regions of the face including the forehead, glabella, lateral canthal rhytides, melolabial folds, nasolabial folds, and perioral rhytides.

They also used a five-point solar lentigines scale to evaluate the change in degree of pigmentation and quantity of age spots as well as the change in rhytid severity before and after PDT and the change in the seven-point Global Aesthetic Improvement Scale (GAIS) to gauge overall improvement of fine lines and wrinkles.

After a mean follow-up of 4.25 months, rhytid severity among the 11 patients was reduced by an average of 0.65 points on the Merz scale, with an SD of 0.20. Broken down by region, rhytid severity scores decreased by 0.2 points (SD, 0.42) for the forehead, 0.7 points (SD, 0.48) for the glabella and lateral canthal rhytides, 0.88 points (SD, 0.35) for the melolabial folds and perioral rhytides, and 0.8 points (SD, 0.42) for the nasolabial folds. (The researchers excluded ratings for the melolabial folds and perioral rhytides in two patients with beards.)

In other findings, solar lentigines grading showed an average reduction of 1 point (SD, 0.45), while the GAIS score improved by 1 or more for every patient, with an average of score of 1.45 (SD, 0.52), showing that some degree of improvement in facial rhytides was noted for all patients following PDT.

“The degree of improvement as measured by our independent physician graders was impressive and not far off from those reported with CO2 ablative laser,” Horton said. “Further, the effect was not isolated to actinic keratoses but extended to improved appearance of fine lines, some deep lines, and lentigines. Although we are not implying that PDT is superior to and should replace lasers or other energy-based devices, it does provide a real, measurable cosmetic benefit.”

Clinicians, he added, can use these findings “to counsel their patients when discussing field cancerization treatment options, especially for patients who may be hesitant to undergo PDT as it can be a painful therapy with a considerable downtime for some.”

Lawrence J. Green, MD, clinical professor of dermatology, The George Washington University, Washington, DC, who was asked to comment on the study results, said that the findings “shine more light on the long-standing off-label use of PDT for lessening signs of photoaging. Like studies done before it, I think this adds an additional benefit to discuss for those who are considering PDT treatment for their actinic keratoses.”

Horton acknowledged certain limitations of the study including its small sample size and the fact that physician graders were not blinded to which images were pre- and post-treatment, “which could introduce an element of bias in the data,” he said. “But this being an unfunded project born out of clinical observation, we hope to later expand its size. Furthermore, we invite other physicians to join us to better study these effects and to design protocols that minimize adverse effects and maximize clinical outcomes.”

His co-authors were Milan Hirpara; Sarah Choe; Joel Cohen, MD; and Natasha A. Mesinkovska, MD, PhD.

Click here to read full article on Medscape.